Chen Yi-Je, Wallace Breanna K, Yuen Natalie, Jenkins David P, Wulff Heike, O'Donnell Martha E
From the Department of Pharmacology (Y.-J.C., D.P.J., H.W.) and Department of Physiology and Membrane Biology (B.K.W., N.Y., M.E.O.), University of California, Davis.
Stroke. 2015 Jan;46(1):237-44. doi: 10.1161/STROKEAHA.114.007445. Epub 2014 Dec 4.
KCa3.1, a calcium-activated potassium channel, regulates ion and fluid secretion in the lung and gastrointestinal tract. It is also expressed on vascular endothelium where it participates in blood pressure regulation. However, the expression and physiological role of KCa3.1 in blood-brain barrier (BBB) endothelium has not been investigated. BBB endothelial cells transport Na(+) and Cl(-) from the blood into the brain transcellularly through the co-operation of multiple cotransporters, exchangers, pumps, and channels. In the early stages of cerebral ischemia, when the BBB is intact, edema formation occurs by processes involving increased BBB transcellular Na(+) transport. This study evaluated whether KCa3.1 is expressed on and participates in BBB ion transport.
The expression of KCa3.1 on cultured cerebral microvascular endothelial cells, isolated microvessels, and brain sections was evaluated by Western blot and immunohistochemistry. Activity of KCa3.1 on cerebral microvascular endothelial cells was examined by K(+) flux assays and patch-clamp. Magnetic resonance spectroscopy and MRI were used to measure brain Na(+) uptake and edema formation in rats with focal ischemic stroke after TRAM-34 treatment.
KCa3.1 current and channel protein were identified on bovine cerebral microvascular endothelial cells and freshly isolated rat microvessels. In situ KCa3.1 expression on BBB endothelium was confirmed in rat and human brain sections. TRAM-34 treatment significantly reduced Na(+) uptake, and cytotoxic edema in the ischemic brain.
BBB endothelial cells exhibit KCa3.1 protein and activity and pharmacological blockade of KCa3.1 seems to provide an effective therapeutic approach for reducing cerebral edema formation in the first 3 hours of ischemic stroke.
KCa3.1是一种钙激活钾通道,可调节肺和胃肠道中的离子及液体分泌。它也表达于血管内皮,参与血压调节。然而,KCa3.1在血脑屏障(BBB)内皮中的表达及生理作用尚未得到研究。BBB内皮细胞通过多种协同转运体、交换体、泵和通道的共同作用,将血液中的Na(+)和Cl(-)跨细胞转运至脑内。在脑缺血早期,当BBB完整时,脑水肿通过涉及BBB跨细胞Na(+)转运增加的过程形成。本研究评估了KCa3.1是否在BBB上表达并参与其离子转运。
通过蛋白质免疫印迹法和免疫组织化学法评估KCa3.1在培养的脑微血管内皮细胞、分离的微血管和脑切片上的表达。通过K(+)通量测定和膜片钳技术检测脑微血管内皮细胞上KCa3.1的活性。采用磁共振波谱和磁共振成像测量TRAM - 34治疗后局灶性缺血性脑卒中大鼠的脑Na(+)摄取和脑水肿形成情况。
在牛脑微血管内皮细胞和新鲜分离的大鼠微血管上鉴定出KCa3.1电流和通道蛋白。在大鼠和人脑切片中证实了BBB内皮原位KCa3.1的表达。TRAM - 34治疗显著降低了缺血脑中的Na(+)摄取和细胞毒性水肿。
BBB内皮细胞表现出KCa3.1蛋白和活性,对KCa3.1的药理学阻断似乎为减少缺血性脑卒中最初3小时内脑水肿形成提供了一种有效的治疗方法。